GlassScriptPhysician profile
Arati C Patel
NPI 1356395388
$3,888.28
in general payments reported to CMS, 2019-2025
43 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $565 · 2021: $344 · 2022: $709 · 2023: $356 · 2024: $108 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.42 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $665.59 | 2019-2025 | Reblozyl, Opdivo |
| Merck Sharp & Dohme LLC | $277.30 | 2019-2025 | Lynparza, Keytruda Qlex, Keytruda |
| Janssen Biotech, INC. | $267.02 | 2019-2025 | Erleada |
| Seagen INC. | $214.60 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $201.13 | 2022-2023 | Fotivda |
| Astrazeneca Pharmaceuticals LP | $177.68 | 2019-2022 | |
| Genentech USA, INC. | $137.96 | 2019 | |
| Amgen INC. | $117.08 | 2019-2022 | |
| Davol INC. | $108.14 | 2024 | |
| Genzyme Corporation | $106.76 | 2019-2023 | |
| Lilly USA, LLC | $101.30 | 2019-2023 | Jaypirca |
| Pfizer INC. | $98.34 | 2019-2020 | |
| Puma Biotechnology, INC. | $96.87 | 2021-2023 | |
| Abbott Laboratories | $86.76 | 2023 | Proclaim |
| Regeneron Healthcare Solutions, INC. | $84.37 | 2019-2025 | Libtayo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arati Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.